Key Account Manager Field Training
Arrowhead Pharmaceuticals
Key Account Manager Field Training
Arrowhead Pharmaceuticals
Develops RNAi-based gene-silencing therapies
Arrowhead Pharmaceuticals, Inc. (Nasdaq ARWR) is a commercial stage biopharmaceutical company that develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.
Arrowhead is focused on developing innovative drugs for diseases with a genetic basis, typically characterized by the overproduction of one or more proteins that are involved with disease. The depth and versatility of our RNAi technologies enables us to potentially address conditions in virtually any therapeutic area and pursue disease targets that are not otherwise addressable by small molecules and biologics. Arrowhead is leading the field in bringing the promise of RNAi to address diseases outside of the liver, and our clinical pipeline includes disease targets in the liver and lung with a promising pipeline of preclinical candidates.
Arrowhead’s corporate headquarters is in Pasadena, CA with research and development teams in Madison, WI & San Diego, CA, and a state of the art manufacturing facility in Verona, WI. Our employees are nimble, science-driven innovators who are collaborating to bring new therapies to patients in need.
The Position
Let’s do something amazing together! The Key Account Manager (KAM) Field Training role at Arrowhead Pharmaceuticals builds the capability of the KAM team to execute Arrowhead’s cardiometabolic brand strategy within health systems and integrated delivery networks. This role serves patients living with Familial Chylomicronemia Syndrome (FCS) and Severe Hypertriglyceridemia (sHTG) and may expand over time to additional indications and products across the Arrowhead cardiometabolic portfolio.
This role owns KAM field readiness end to end: designing, developing, delivering, and measuring the curriculum that prepares Key Account Managers for account-based selling in complex health systems. Partners with Marketing to translate approved strategy and approved materials into training that drives confident, compliant field execution.
Reporting to the Director, Sales Training, this individual partners closely with Marketing, Field leadership, Market Access, Market Insights, Medical Affairs, Health Information Technology, Regulatory, and Compliance. Success requires deep fluency in integrated delivery network (IDN) structure and workflow, specialty pharmacy and access dynamics, and the instructional design discipline to turn that complexity into training adult learners can apply the same week.
This individual should be detail-oriented, an excellent communicator and facilitator, comfortable in a fast-paced launch environment, and effective working both independently and collaboratively.
This is a field-based role with regular onsite presence at Arrowhead’s Corporate Headquarters in Pasadena, CA. Time will be split between the field supporting training delivery, live facilitation, and field ride-alongs with the KAM team and headquarters, partnering with cross-functional stakeholders.
Responsibilities
Curriculum Design and Development
Training Delivery and Facilitation
Certification, Measurement, and LMS Ownership
Cross-Functional Collaboration
MLR and Compliance
Budget and Planning
Core Competencies and Behaviors
Requirements
Preferred
Arrowhead provides competitive salaries and an excellent benefit package.
Candidates must have current, valid authorization to work in the country where this role is located.
California pay range 180000 - 220000 USD
Develops RNAi-based gene-silencing therapies
Arrowhead Pharmaceuticals develops medicines using RNA interference (RNAi) to silence disease-causing genes. The company’s approach uses a library of RNA chemistries and delivery methods to trigger RNAi, enabling rapid and durable reduction of target gene expression in cells. This gene-silencing strategy aims to treat severe genetic diseases such as cystic fibrosis and hepatitis B by lowering disease-related proteins. Arrowhead’s products are advanced through discovery and development partnerships, licensing deals, and potential commercialization of approved therapies. The company differentiates itself through a broad RNAi platform, proprietary delivery tech, and collaborations with larger pharma firms to advance its pipeline. Its goal is to provide new treatment options for conditions with limited or no effective therapies by translating gene silencing into medicines that can halt or reverse disease progression.
Explore more opportunities at Arrowhead Pharmaceuticals